472 related articles for article (PubMed ID: 35333651)
1. Structural determinants of dual incretin receptor agonism by tirzepatide.
Sun B; Willard FS; Feng D; Alsina-Fernandez J; Chen Q; Vieth M; Ho JD; Showalter AD; Stutsman C; Ding L; Suter TM; Dunbar JD; Carpenter JW; Mohammed FA; Aihara E; Brown RA; Bueno AB; Emmerson PJ; Moyers JS; Kobilka TS; Coghlan MP; Kobilka BK; Sloop KW
Proc Natl Acad Sci U S A; 2022 Mar; 119(13):e2116506119. PubMed ID: 35333651
[TBL] [Abstract][Full Text] [Related]
2. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
3. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
Mayendraraj A; Rosenkilde MM; Gasbjerg LS
Peptides; 2022 May; 151():170749. PubMed ID: 35065096
[TBL] [Abstract][Full Text] [Related]
6. Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP.
Wang L
Drug Des Devel Ther; 2022; 16():1547-1559. PubMed ID: 35651477
[TBL] [Abstract][Full Text] [Related]
7. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
8. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.
Zhao F; Zhou Q; Cong Z; Hang K; Zou X; Zhang C; Chen Y; Dai A; Liang A; Ming Q; Wang M; Chen LN; Xu P; Chang R; Feng W; Xia T; Zhang Y; Wu B; Yang D; Zhao L; Xu HE; Wang MW
Nat Commun; 2022 Feb; 13(1):1057. PubMed ID: 35217653
[TBL] [Abstract][Full Text] [Related]
10. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets.
El K; Douros JD; Willard FS; Novikoff A; Sargsyan A; Perez-Tilve D; Wainscott DB; Yang B; Chen A; Wothe D; Coupland C; Tschöp MH; Finan B; D'Alessio DA; Sloop KW; Müller TD; Campbell JE
Nat Metab; 2023 Jun; 5(6):945-954. PubMed ID: 37277609
[TBL] [Abstract][Full Text] [Related]
11. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
Gasbjerg LS; Rosenkilde MM; Meier JJ; Holst JJ; Knop FK
Diabetes Obes Metab; 2023 Nov; 25(11):3079-3092. PubMed ID: 37551549
[TBL] [Abstract][Full Text] [Related]
12. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
[TBL] [Abstract][Full Text] [Related]
13. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
[TBL] [Abstract][Full Text] [Related]
14. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
[TBL] [Abstract][Full Text] [Related]
15. GIP-derived GIP receptor antagonists - a review of their role in GIP receptor pharmacology.
Rosenkilde MM; Lindquist P; Kizilkaya HS; Gasbjerg LS
Peptides; 2024 Jul; 177():171212. PubMed ID: 38608836
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells.
Manchanda Y; Bitsi S; Chen S; Broichhagen J; Bernardino de la Serna J; Jones B; Tomas A
Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36774542
[TBL] [Abstract][Full Text] [Related]
17. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.
Samms RJ; Christe ME; Collins KA; Pirro V; Droz BA; Holland AK; Friedrich JL; Wojnicki S; Konkol DL; Cosgrove R; Furber EPC; Ruan X; O'Farrell LS; Long AM; Dogra M; Willency JA; Lin Y; Ding L; Cheng CC; Cabrera O; Briere DA; Alsina-Fernandez J; Gimeno RE; Moyers JS; Coskun T; Coghlan MP; Sloop KW; Roell WC
J Clin Invest; 2021 Jun; 131(12):. PubMed ID: 34003802
[TBL] [Abstract][Full Text] [Related]
18. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.
Mathiesen DS; Bagger JI; Bergmann NC; Lund A; Christensen MB; Vilsbøll T; Knop FK
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443356
[TBL] [Abstract][Full Text] [Related]
20. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Willard FS; Douros JD; Gabe MB; Showalter AD; Wainscott DB; Suter TM; Capozzi ME; van der Velden WJ; Stutsman C; Cardona GR; Urva S; Emmerson PJ; Holst JJ; D'Alessio DA; Coghlan MP; Rosenkilde MM; Campbell JE; Sloop KW
JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32730231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
